Mismatch between bone marrow transplant (BMT) patient and donor for an amino acid polymorphism within the adhesion molecule CD31 has recently been reported to increase risk for the development of graft-versus-host disease (GVHD). We further examined this association in a larger series of 301 BMT patients (227 with grade III/IV GVHD and 74 with grade 0 GVHD) and their HLA-identical sibling donors. CD31 genotypes were determined by polymerase chain reaction and restriction endonuclease digestion. The role of mismatch at the CD31 locus in the development of GVHD was assessed by analyzing the extent of CD31 identity and CD31 compatibility among the grade 0 GVHD and grade Ill/ IV GVHD sibling pairs. No significant association between CUTE GRAFT-VERSUS-HOST disease (GVHD) is a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT)."3 Compatibility at the major histocompatibility complex (MHC) is a primary determinant of GVHD. Most recipients of marrow from HLA-mismatched donors develop GVHD.4.5 However, despite compatibility at the major loci, 10% to 40% of HLAidentical sibling donor transplant recipients and 60% to 80% of recipients of marrow from an HLA-compatible unrelated donor develop clinically significant GVHD.2.6-10 Significant GVHD generally does not develop after either BMT between identical twins or autologous BMT. These observations indicate that heritable differences encoded by genes outside the MHC, generally referred to as minor histocompatibility antigens, are responsible for the development of acute GVHD in HLA-identical sibling transplants.lL.12
recently, no clinically important minor histocompatibility antigen had been identified in humans except for the H-Y antigen.14 van Els et all3 have identified five autosomal minor histocompatibility antigens (HA-l, -2, -3, -4, and -5) through the isolation of cytotoxic T-cell clones from lymphocyte populations in the blood of patients with severe GVHD. HA-1, -2, -4, and -5 are detected only in individuals expressing HLA-A2, whereas HA-3 is restricted in presentation by HLA-A1. 15 The nine amino acid peptide corresponding to HA-2 appears to be derived from an as yet uncharacterized human class I myosin protein. 16 In a recent study, Goulmy et all5 observed a significant correlation of GVHD with recipient and donor mismatch at HA-1 alone or HA- 1 and one or more mismatches of HA-2, -4, and -5.
Behar et all' recently reported an association between GVHD and mismatch at an amino acid polymorphism (leucine or valine at codon 125) within the adhesion molecule CD31 or PECAM-l.'s. '9 In a retrospective study of 14 HLAidentical, grade IIMV GVHD and 32 HLA-identical, grade 0 GVHD recipienvdonor pairs, recipients of BM from CD3 1 -nonidentical donors were found to have a substantially CD31 mismatch and the development of severe GVHD was detected in our overall patient population. Sixty-three percent of grade III/IV GVHD sibling pairs and 699'0 of grade 0 GVHD sibling pairs had CD31 genotypes that were identical ( P = .36, odds ratio = 1.30). In addition. neither the grade 0 GVHD group (P = .lo) nor the grade III/IV GVHD group (P = .27) differed significantly from the expected probability of identity between sibling pairs. Mismatch at the CD31 polymorphism between recipients and donors showed no consistent association with the development of GVHD. Current evidence does not support the value of CD31 mismatch in the selection of BMT donors. 0 1996 by The American Society of Hematology.
higher risk of acute GVHD than recipients of CD3 l-identical marrow.17 We examined the correlation of patient and donor CD31 genotype with the development of acute GVHD in a considerably larger set of patients from six transplant centers. We observed no significant association between CD31 mismatch and the development of severe GVHD in our patient population. Detection of CD3l L.eitcine/Vuline codon 125 polwnorphian. A total of 7.5 mL of each CD31 PCR product was digested with IO U of either Alu I or P i u I1 at 37°C as directed by the manufacturer (BRL, Gaithersburg, MD). All PCR products were digested independently with each restriction enzyme as confirmation of the leucine/ valine codon 125 polymorphism. The presence of an A h I or Piw I1 site at position 121 of the 191-bp PCR product indicates leucine at codon 125, whereas the absence of both sites indicates valine at codon 125. Restriction endonuclease digestion products were separated by electrophoresis through 4% composite (3% BRL, l o/c FMC Bioproducts) agarose and visualized by staining with ethidium bromide (Fig IA) .
Recipients Donors
A 457-bp fragment of the HLA-A2 gene was amplified as previously described'4 using the same conditions as described above, except for an annealing temperature of 54°C. PCR products were separated by electrophoresis through 2% agarose and visualized by staining with ethidium bromide. Individuals carrying at least one HLA-A2 allele were identified by the presence of a 457-bp PCR product, whereas those individuals not carrying an HLA-A2 allele showed no PCR product (Fig IB) .
The statistical significance of differences between groups for Tables 2 and 3 was calculated using the xZ test for heterogeneity. Fisher's exact test was used for calculations of statistical significance in Table 4 because of small sample size. Odds ratios and 95% confidence intervals were computed by standard methods."
Detection of HL4-A2 genomic .sequences.
Statistical unu/.v.ses.

RESULTS
We analyzed DNA samples prepared from 227 transplant patients with grade III/IV GVHD and their HLA-identical sibling marrow donors as well as 74 grade 0 GVHD recipient/donor sibling pairs for the CD3 1 leucine/valine codon I25 polymorphism. Because grade 1/11 GVHD is less reliably differentiated from other causes of BMT-related toxicity, we chose to collect only grade III/IV GVHD sibling pairs to maximize the chance that the affected pairs had authentic GVHD due to incompatibility at one or more minor histocompatibility loci. The C to G transversion substituting valine for leucine at codon 125 results in the loss of both an A h I restriction endonuclease site and a Pwr I1 restriction endonuclease site. All PCR products were digested with Alii I to determine patient genotypes and, as confirmation, were also digested with Pvu I1 (Fig IA) . Results of the Piw I1 digests were completely concordant with the Alii I results. Allele frequencies were estimated using all recipient and donor siblings, taking the family relationships into account.'" In our population of 301 BMT patients and their HLA-identical sibling donors, the leucine allele had a frequency of 0.501 and the valine allele had a frequency of 0.499. This is consistent with the frequencies reported by Behar et al."
The frequencies of the nine possible sibling pair genotype combinations can be estimated using the allele frequencies of the leucine and valine alleles (Table I) . For example, if the recipient is a leucineneucine homozygote and the donor is a valine/valine homozygote, then both parents must be leucine/valine heterozygotes. Assuming Hardy-Weinberg equilibrium, the frequency of the leucine/valine genotype in the population is 0.50. The probability that two heterozygous parents would produce either type of homozygous child is 1/4. Thus, the probability that we would observe a leucine/ leucine, valine/valine recipient/donor pair is (0.50)(0.50)( I/ 4)( 1/4) = 0.0156. The frequencies of the other 8 sibling pair genotype combinations are calculated in a similar fashion.
Comparison of the CD3 I genotyping between our patients and their HLA-identical sibling donors is shown in Table 2 . Based on the estimated frequencies of the nine different recipient/donor genotype combinations, the probability that the siblings will have identical genotypes is 0.594 (Table I) . As seen, 69% of grade 0 GVHD recipieddonor pairs had identical genotypes for the CD3 I polymorphism, whereas
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The estimated probability of identity is 0.594. The estimated probability of compatibility is 0.781. Those frequencies shown in bold represent identity between sibling pairs and those underlined represent compatibility. Incompatibility is defined as the presence of a CD31 allele in the BMT recipient that would be recognized as foreign to the donor. For example, although LeuNal and Leu/Leu are nonidentical, a LeuNal donor is compatible with a Leu/Leu recipient, whereas a Leu/ Leu donor is incompatible with a LeuNal recipient. Incompatibility is expected to be more predictive of GVHD than nonidentity.
63% of acute severe GVHD recipient/donor pairs were identical. This difference between the two groups for identity was not statistically significant (x2 = 0.85, df = 1, P = .36).
In fact, the odds ratio for severe GVHD in patients with CD31-nonidentical donors as compared with patients with CD31-identical donors was 1.30 (95% confidence interval [CI], 0.74 to 2.28). Also, neither the grade 0 GVHD group (x2 = 2.78, df = 1, P = .lo) nor the grade III/IV GVHD group (x2 = 1.22, df = 1, P = .27) differed significantly from the expected probability of identity between sibling pairs (0.594), although the grade 0 GVHD group is skewed towards greater identity than expected. In contrast to the findings of Behar et al,I7 these data from a much larger cohort of patients failed to show a strong association of mismatch at the CD31 leucinehaline codon 125 polymorphism with an increased risk of severe (grade III/IV) GVHD. In the data from Behar et a]," 25 of 32 (0.78) grade 0 GVHD recipientldonor pairs shared identical genotypes, whereas only 4 of 14 (0.29) grade IIVIV GVHD pairs were identical.
1
Given our sample size of 74 grade 0 and 227 grade III/IV GVHD sibling pairs, we have greater than 99.99% power to detect an effect of the magnitude detected by Behar et all' at the .05 level of significance.
By analogy to HLA, incompatibility for the CD31 polymorphism (ie, the presence of a CD31 allele in the BM recipient that is foreign to the donor and thus a potential minor histocompatibility antigen) should be more relevant as a determinant of GVHD than genotype nonidentity. For example, a leucineneucine or valinehaline recipient would not be expected to elicit a GVHD response from a compatible but nonidentical leucinehaline donor marrow. Based on the estimated frequencies of the sibling pair genotype combinations (Table l) , the estimated probability of compatibility between unselected sibling pairs is 0.781 and incompatibility is 0.219. Whereas 85% of grade 0 GVHD pairs were compatibile at the CD3 I codon 125 polymorphism, 77% were compatible in the grade IIVIV GVHD group (Table 2) . This difference between groups is not statistically significant (x2 = 2.18, df = 1, P = .14). In addition, neither the grade 0 GVHD group (x2 = 2.14, df = 1, P = .14) nor the grade III/IV GVHD group (x' = 0.13, df = 1, P = .71) differed significantly from the expected frequency of compatibility. The odds ratio for severe GVHD in patients with CD31-incompatible donors as compared with patients with CD31-compatible donors was 1.70 (95% CI, 0.83 to 3.47).
Minor histocompatibility antigens are expected to be restricted in their presentation by the MHC.27.28 To determine whether mismatch at CD31 and its role in GVHD is MHC restricted, stratification of the data by HLA type was necessary. HLA-A2, the most common HLA antigen, has a reported allele frequency of -0.27, with -47% of individuals carrying at least one HLA-A2 allele.'5~29~30 Goulmy et all5 recently reported a correlation between mismatch at an HLA-A2-restricted minor antigen (HA-l) and the development of GVHD. If the contribution of CD3 I mismatch to GVHD is similarly MHC restricted, then a significant effect in a Pvalues at the far right represent comparisons of grade lll/lV GVHD sibling pairs to grade 0 GVHD sibling pairs; Pvalues below the subgroups represent comparisons of the observed to the expected. Incompatibility between recipient and donor is defined as in Table 1 .
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specific HLA subset could be missed in analysis of the full set of sibling pairs. However, only HLA-A2 has a sufficiently high allele frequency to define a large enough cohort for further analysis. We thus examined mismatch at the CD31 locus between recipient and donor as a risk factor for GVHD after stratification for the presence or absence of HLA-A2. All grade IIVIV and grade 0 GVHD sibling pairs were genotyped for HLA-A2 by PCR (Fig 1B) and reanalyzed for an association between CD31 mismatch and GVHD. Our estimated HLA-A2 allele frequency of 0.276 in 301 BMT recipient and donor pairs is in agreement with that reported p r e v i o~s l y . '~~'~~~" As seen in Table 3 , 79% of pairs in the HLA-A2-positive, grade 0 GVHD group showed identity, whereas only 58% of pairs in the HLA-A2 positive, grade IIVIV GVHD group showed identity. This difference is statistically significant (x2 = 4.62, df = 1, P = .03; odds ratio = 2.67; 95% CI, 1.07 to 6.68) but is due primarily to the greater proportion of identity observed among the grade 0 recipienudonor pairs than the predicted value of 0.594 (x' = 5.14, df = 1, P = .02). The proportion of identity in the grade IIVIV group did not differ significantly from expected (x' = 0.07, df = l , P = .79). In an analysis for compatibility rather than for identity, this difference between the HLA-A2, grade 0, and grade III/IV groups no longer reaches traditional levels of statistical significance, although the trend remains (x2 = 3.22, df = 1, P = .07; odds ratio = 2.72; 95% CI, 0.88 to 8.39). The HLA-A2-negative patient pairs showed no significant difference when analyzed either for identity (x' = 0.58, df = 1, P = .45; odds ratio = 0.75; 95% CI, 0.36 to 1.57) or compatibility (x2 = 0.36, df = 1, P = .55; odds ratio = 1.35; 95% CI, 0.51 to 3.61; Table 3 ).
In light of the above data, we re-evaluated the results of Behar et a1" according to the presence or absence of HLA-P = .03 P = .07 P = .45 A2. Table 4 shows a stratification by HLA-A2 type of the data originally reported by Behar et al" (Nelson J. Chao, personal communication, April 17, 1996) . In contrast to our results, the difference between the HLA-A2, grade 0 GVHD group and the HLA-A2, grade IIVIV GVHD group is not significant when analyzed for either identity ( P = .52) or compatibility ( P = .70) between sibling pairs. However, again in contrast to our results, comparison for either identity ( P = .0002) or compatibility ( P = .OM) between the non- Pvalues at the far right represent comparisons of grade III/IV GVHD sibling pairs to grade 0 GVHD siblir.3 pairs. Incompatibility between recipient and donor is defined as in Table 1 .
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DISCUSSION
Comparison of CD31 polymorphism genotypes between our 74 grade 0 GVHD recipieddonor pairs and 227 grade IIVIV GVHD recipienudonor pairs failed to detect a significant difference, except possibly for a subgroup of sibling pairs that is HLA-A2 positive. Whereas Behar et all7 observed odds ratios of 8.93 and 7.25 for nonidentity versus identity and incompatibility versus compatibility, respectively, we obtained odds ratios only slightly greater than 1 .O for the same comparisons. Re-examination of the data of Behar et all7 shows that the difference between their 32 grade 0 GVHD pairs and 14 grade IIMV GVHD pairs is due primarily to a marked discordance among their non-HLA-A2 sibling pairs. Taken together, these data call into question the hypothesis that mismatch at CD31 plays a significant role in the development of GVHD after allogeneic BMT.
The most significant differences observed in our study appeared to arise from an increased proportion of identity among the grade 0 recipientldonor pairs than would be predicted. We excluded grade VI1 GVHD sibling pairs from our GVHD group to maximize the chance that the affected pairs had authentic GVHD due to incompatibility at a minor histocompatibility locus because grade MI GVHD is less reliably differentiated from other causes of BMT-related toxicity. With current GVHD prophylaxis regimens, only 10% to 15% of BMT patients develop grade IIVIV GVHD.' As a result, many grade 0 GVHD recipient/donor sibling pairs would be expected to have minor histocompatibility antigen mismatches that might have elicited a graft-versus-host response in the absence of immunosuppressive therapy or T-cell depletion. Thus, the grade 0 GVHD patient group is only minimally selected over the general population. With this consideration, our data and that of Behar et al,I7 which also shows statistical significance for increased identity in their grade 0 GVHD group (P = .03), are difficult to reconcile in the absence of an expected significant decrease in identity (or compatibility) for a minor histocompatibility antigen in the grade IIMV GVHD recipient/donor pairs. CD31 has previously been mapped to the long arm of human chromosome 17 (17q23-qter).31 Behar et all7 speculate that the apparent association between CD31 mismatch and GVHD could also be due to another locus on chromosome 17 that is linked to CD31. As part of a large, ongoing study to identify non-HLA loci contributing to GVHD, we have also genotyped 77 to 177 grade III/IV GVHD recipient/ donor pairs reported here for seven tetranucleotide short tandem repeat (STR) polymorphisms spanning the long arm of chromosome 17. None of these markers shows a significant increase in dissimilarity between recipient and donor that would be indicative of an STR linked to a non-HLA GVHD locus (W. Nichols, unpublished data).
Genetic disparities at minor histocompatibility loci between BMT patients and their HLA-identical sibling marrow donors are likely to play a significant role in the development of GVHD. The identification of such minor histocompatibility loci would permit typing for these genes before BMT as an adjunct to standard HLA typing for the selection of rnarrow donors. This approach might significantly lower the incidence of GVHD and could extend the use of unrelated marrow donors as well as guide the choice of GVHD prophylaxis regimens. The major clinical impact that could follow from successful mapping of minor histocompatibility genes lent considerable excitement to the recent reports of Behar et all7 and Goulmy et Although the CD31 mismatch reported by Behar et a l l 7 can be detected by a simple PCR-based assay that is easily applicable to the routine clinical laboratory, our current analysis of a large data set does not confirm the value of this marker in the prediction of GVHD risk. In light of our contradictory findings in a substantially larger patient population, current evidence does not support the clinical application of mismatch at CD31 in the selection of BM donors. However, it is likely that the future identification of one or more clinically relevant minor histocompatibility gene polymorphisms by similar genetic analysis will lead to major improvements in the selection of donors for allogeneic BMT.
